Colombat P, Donadio D, Fouillard L, Milpied N, Tilly H, Pico J, Abgrall J F, Coiffier B, Herbrecht R, Philip T
Department of Haematology and Oncology, CHU Bretonneau, Tours, France.
Bone Marrow Transplant. 1994 Feb;13(2):157-62.
The value of high-dose chemotherapy with hematologic stem cell rescue has not been established in the treatment of low-grade non-Hodgkin's lymphoma. We report the results of a retrospective 'France Autogreffe' study of 42 patients grafted in first partial remission (n = 13) or chemosensitive relapse (n = 29) for follicular lymphoma before January 1990. The median age was 38 years (range 26-61 years). Preparative therapy was chemotherapy alone in 22 patients and total body irradiation (TBI)-containing regimens in 20 patients. Thirty-seven patients received hematopoietic marrow stem cells. Bone marrow purging was performed in 15 patients. Five patients received peripheral blood stem cells. Three patients died of bone marrow transplantation toxicity and two others died in complete remission 10 months after autologous bone marrow transplantation. With a median follow-up of 43 months, relapse-free survival is 60%, event-free survival 58% and overall survival 83%. To date no prognostic factors have been shown.
高剂量化疗联合血液学干细胞救援在低度非霍奇金淋巴瘤治疗中的价值尚未确定。我们报告了一项回顾性的“法国自体移植”研究结果,该研究纳入了1990年1月前因滤泡性淋巴瘤处于首次部分缓解(n = 13)或化疗敏感复发(n = 29)状态而接受移植的42例患者。中位年龄为38岁(范围26 - 61岁)。22例患者的预处理方案仅为化疗,20例患者采用含全身照射(TBI)的方案。37例患者接受了造血骨髓干细胞。15例患者进行了骨髓净化。5例患者接受了外周血干细胞。3例患者死于骨髓移植毒性,另外2例在自体骨髓移植10个月后完全缓解状态下死亡。中位随访43个月,无复发生存率为60%,无事件生存率为58%,总生存率为83%。迄今为止,尚未发现预后因素。